Abstract: OBJECTIVE To multi-dimensional analyze registration information of clinical trials of COVID-19, so as to provide data and experience for other clinical trials during the epidemic control period. METHODS Overall situation of registered projects was objectively evaluated in terms of clinical trial design, study type, number of centres, the location of the group leader, and subject population by searching through both of the Chinese Clinical Trial Registry site(Chictr.org.cn) and the National Institutes of Health clinical trial registration platform(ClinicalTrials.gov). In addition, from the perspective of the research object, the related trials of both listed medication and non-medication treatments were discussed. RESULTS By February 7, 2020, a total of 45 clinical trials had been registered, of which 41(91.1%) were medication therapy clinical trials. The number of items involved in antiviral therapy, hormone therapy, and traditional Chinese medicine treatment was 18, 2 and 21, respectively. Randomized controlled clinical trials were the common study designs in registered programs and 44(97.8%) were intervention studies among the statistics. Most of the group leaders were located in Hubei, Beijing, Zhejiang and Guangdong, and the proportion of sample size within 100 cases(≤ 100) was relatively large(51.1%). CONCLUSION In the absence of specific medication treatment for the current outbreak, the rapid development of clinical trials of the therapeutic drugs can provide a more favourable chance of seeking suitable drug treatment options and suppress the pandemic.